Ionis Initiates P-III CORE Study of Olezarsen for the Treatment of Severe Hypertriglyceridemia
Shots:
- The company initiates second P-III CORE study to evaluate olezarsen vs PBO in patients with severe hypertriglyceridemia who are on the currently available SoC therapies for elevated triglycerides
- The 1EPs of the study is the percent change in fasting triglycerides from baseline @6mos. The 2EPs include percent change from baseline in triglycerides @12mos. & in other atherogenic lipids @6 & 12mos. & the proportion of patients who achieve fasting triglycerides =500/880/1000 mg/dL
- In P-II clinical study, olezarsen met its 1EPs & 2EPs i.e., reductions in triglyceride & apoC-III levels, favorable safety & tolerability profile, 91% of patients achieved a normal triglyceride level of <150 mg/dL
| Ref: PR Newswire | Image: Wikipedia
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com